These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16135565)

  • 21. The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders.
    Pozzi C; Di Pisa F; Benvenuti M; Mangani S
    J Biol Inorg Chem; 2018 Dec; 23(8):1219-1226. PubMed ID: 30132075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site.
    Booth RE; Lovell SC; Misquitta SA; Bateman RC
    BMC Biol; 2004 Feb; 2():2. PubMed ID: 15028118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ.
    Schilling S; Appl T; Hoffmann T; Cynis H; Schulz K; Jagla W; Friedrich D; Wermann M; Buchholz M; Heiser U; von Hörsten S; Demuth HU
    J Neurochem; 2008 Aug; 106(3):1225-36. PubMed ID: 18627432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydrazides Are Potent Transition-State Analogues for Glutaminyl Cyclase Implicated in the Pathogenesis of Alzheimer's Disease.
    Kupski O; Funk LM; Sautner V; Seifert F; Worbs B; Ramsbeck D; Meyer F; Diederichsen U; Buchholz M; Schilling S; Demuth HU; Tittmann K
    Biochemistry; 2020 Jul; 59(28):2585-2591. PubMed ID: 32551535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of glutaminyl cyclase attenuates cell migration modulated by monocyte chemoattractant proteins.
    Chen YL; Huang KF; Kuo WC; Lo YC; Lee YM; Wang AH
    Biochem J; 2012 Mar; 442(2):403-12. PubMed ID: 22060158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for essential histidines in human pituitary glutaminyl cyclase.
    Bateman RC; Temple JS; Misquitta SA; Booth RE
    Biochemistry; 2001 Sep; 40(37):11246-50. PubMed ID: 11551224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural and kinetic characterization of
    Lamers S; Feng Q; Cheng Y; Yu S; Sun B; Lukman M; Jiang J; Ruiz-Carrillo D
    Biol Chem; 2021 Jun; 402(7):759-768. PubMed ID: 33823093
    [No Abstract]   [Full Text] [Related]  

  • 28. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
    Morawski M; Schilling S; Kreuzberger M; Waniek A; Jäger C; Koch B; Cynis H; Kehlen A; Arendt T; Hartlage-Rübsamen M; Demuth HU; Roßner S
    J Alzheimers Dis; 2014; 39(2):385-400. PubMed ID: 24164736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probing secondary glutaminyl cyclase (QC) inhibitor interactions applying an in silico-modeling/site-directed mutagenesis approach: implications for drug development.
    Koch B; Buchholz M; Wermann M; Heiser U; Schilling S; Demuth HU
    Chem Biol Drug Des; 2012 Dec; 80(6):937-46. PubMed ID: 22967026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.
    Hartlage-Rübsamen M; Bluhm A; Moceri S; Machner L; Köppen J; Schenk M; Hilbrich I; Holzer M; Weidenfeller M; Richter F; Coras R; Serrano GE; Beach TG; Schilling S; von Hörsten S; Xiang W; Schulze A; Roßner S
    Acta Neuropathol; 2021 Sep; 142(3):399-421. PubMed ID: 34309760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substrate specificity of glutaminyl cyclases from plants and animals.
    Schilling S; Manhart S; Hoffmann T; Ludwig HH; Wasternack C; Demuth HU
    Biol Chem; 2003 Dec; 384(12):1583-92. PubMed ID: 14719800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The soluble Y115E-Y117E variant of human glutaminyl cyclase is a valid target for X-ray and NMR screening of inhibitors against Alzheimer disease.
    DiPisa F; Pozzi C; Benvenuti M; Andreini M; Marconi G; Mangani S
    Acta Crystallogr F Struct Biol Commun; 2015 Aug; 71(Pt 8):986-92. PubMed ID: 26249687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region.
    Ngo VTH; Hoang VH; Tran PT; Ann J; Cui M; Park G; Choi S; Lee J; Kim H; Ha HJ; Choi K; Kim YH; Lee J
    Bioorg Med Chem; 2018 Mar; 26(5):1035-1049. PubMed ID: 29398442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
    Hartlage-Rübsamen M; Morawski M; Waniek A; Jäger C; Zeitschel U; Koch B; Cynis H; Schilling S; Schliebs R; Demuth HU; Rossner S
    Acta Neuropathol; 2011 Jun; 121(6):705-19. PubMed ID: 21301857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship.
    Buchholz M; Heiser U; Schilling S; Niestroj AJ; Zunkel K; Demuth HU
    J Med Chem; 2006 Jan; 49(2):664-77. PubMed ID: 16420052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Papaya glutamine cyclotransferase shows a singular five-fold beta-propeller architecture that suggests a novel reaction mechanism.
    Guevara T; Mallorquí-Fernández N; García-Castellanos R; García-Piqué S; Ebert Petersen G; Lauritzen C; Pedersen J; Arnau J; Gomis-Rüth FX; Solà M
    Biol Chem; 2006; 387(10-11):1479-86. PubMed ID: 17081122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells.
    Cynis H; Schilling S; Bodnár M; Hoffmann T; Heiser U; Saido TC; Demuth HU
    Biochim Biophys Acta; 2006 Oct; 1764(10):1618-25. PubMed ID: 17005457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases.
    Zhang Y; Wang Y; Zhao Z; Peng W; Wang P; Xu X; Zhao C
    Eur J Pharmacol; 2022 Sep; 931():175178. PubMed ID: 35948163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linked production of pyroglutamate-modified proteins via self-cleavage of fusion tags with TEV protease and autonomous N-terminal cyclization with glutaminyl cyclase in vivo.
    Shih YP; Chou CC; Chen YL; Huang KF; Wang AH
    PLoS One; 2014; 9(4):e94812. PubMed ID: 24733552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity.
    Kehlen A; Haegele M; Böhme L; Cynis H; Hoffmann T; Demuth HU
    Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28739588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.